MR. ROBERT W ANDREWS, MD
Urology at Frasier St, Durham, NC

6329400, Dec 11, 2001

Aug 25, 1999

9/382924

Robert Carl Andrews - Durham NC
Marc Werner Andersen - Raleigh NC
Dulce Garrido Bubacz - Cary NC
Joseph Howing Chan - Chapel Hill NC
David John Cowan - Hillsborough NC
Michael David Gaul - Apex NC
Daryl Lynn McDougald - Durham NC
David Lee Musso - Raleigh NC
Michael Howard Rabinowitz - Durham NC
Jennifer Badiang Stanford - Cary NC
Robert William Wiethe - Durham NC

Glaxo Wellcome Inc. - Research Triangle Park NC

C07D40912, C07D21374, A61K 314436, A61K 314409

514336

A family of compounds having the general structural formula ##STR1## where W is a reverse hydroxamic acid group, and R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 5 and R. sub. 6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.

6172064, Jan 9, 2001

Aug 25, 1999

9/382333

Robert Carl Andrews - Durham NC
Marc Werner Andersen - Raleigh NC
David John Cowan - Hillsborough NC
David Norman Deaton - Cary NC
Scott Howard Dickerson - Chapel Hill NC
David Harold Drewry - Durham NC
Michael David Gaul - Apex NC
Michael Joseph Luzzio - Durham NC
Brian Edward Marron - Durham NC
Michael Howard Rabinowitz - Durham NC

Glaxo Wellcome Inc. - Research Triangle Park NC

C07D21170, C07D20708, C07D33322, C07C25904, A61K 31535, A61K 3140, A61K 3138, A61K 3119, A61K 3144

5142378

A family of compounds having the general structural formula ##STR1## where W is a reverse hydroxamic acid group, and R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 5 and R. sub. 6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof. Also described are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine.

6191150, Feb 20, 2001

Aug 25, 1999

9/382747

Robert Carl Andrews - Durham NC
Marc Werner Andersen - Raleigh NC
Dulce Garrido Bubacz - Cary NC
Joseph Howing Chan - Chapel Hill NC
David John Cowan - Hillsborough NC
Michael David Gaul - Apex NC
Daryl Lynn McDougald - Durham NC
David Lee Musso - Raleigh NC
Michael Howard Rabinowitz - Durham NC
Jennifer Badiang Stanford - Cary NC
Robert William Wiethe - Durham NC

Glaxo Wellcome Inc. - Research Triangle Park NC

A61K 3144, A61K 31425, A61K 3138, A61K 31215, C07D21172

514352

A family of compounds having the general structural formula ##STR1## where W is a reverse hydroxamic acid group, and R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 5 and R. sub. 6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.

6090825, Jul 18, 2000

Jun 3, 1997

8/849016

Robert Carl Andrews - Durham NC
Peter Jonathan Brown - Chapel Hill NC
Rodolfo Cadilla - Durham NC
David Harold Drewry - Durham NC
Michael Joseph Luzzio - Durham NC
Brian Edward Marron - Durham NC
Stewart Alwyn Noble - Upper Saddle NJ

Glaxo Wellcome Inc. - Research Triangle Park NC

A61K 31445, C07D41302, A61P 906, A61P 1714

514326

Oxazole compounds having formula (I) wherein R. sup. 1 and R. sup. 3 are selected from the group consisting of hydrogen, hydroxy, C. sub. 1-6 alkyl, C. sub. 1-6 alkoxy, C. sub. 1-6 alkoxyC. sub. 1-6 alkyl, phenyl or phenyl mono- or disubstituted with C. sub. 1-6 alkyl, halogen, hydroxy, C. sub. 1-6 alkoxy, aminosulfonyl, hydroxyC. sub. 1-6 alkyl, C. sub. 1-6 alkylsulfonylaminoC. sub. 1-6 alkyl or carbamylC. sub. 1-6 alkylaminosulfonyl; R. sup. 2 is selected from hydrogen, C. sub. 1-6 alkyl, hydroxyC. sub. 1-6 alkyl, C. sub. 1-6 alkoxy, C. sub. 1-6 alkoxyC. sub. 1-6 alkyl or (fluorinated C. sub. 1-6 alkyl)oxyC. sub. 1-6 alkyl; W is a C. sub. 1-6 alkylene chain or nitrogen; m is independently the integer 0 or 1; X is CH or nitrogen, provided that when W is nitrogen then X is CH; q is independently an integer selected from the group consisting of 1, 2, 3 or 4; or a pharmaceutically acceptable acid-addition or base-addition salt thereof, pharmaceutical compositions containing them and their use in therapy. ##STR1##.

5543406, Aug 6, 1996

Aug 15, 1994

8/244875

Robert C. Andrews - Durham NC
Cynthia M. Cribbs - Raleigh NC
Stephen V. Frye - Durham NC
Curt D. Haffner - Cary NC
Patrick R. Maloney - Durham NC

Glaxo Wellcome, Inc. - Research Triangle Park NC

A61K 3140, A61K 31435, A61K 3155

514213

The present invention relates to certain substituted 17. beta. -substituted carbonyl-6-azaandrost-4-en-3-ones of formula (I), especially those of formula (IG) ##STR1## wherein R. sup. 1 and R. sup. 2 are i) independently hydrogen or lower alkyl and the bond between the carbons bearing R. sup. 1 and R. sup. 2 is a single or a double bond, or ii) taken together are a --CH. sub. 2 -- group to form a cyclopropane ring, and the bond between the carbons bearing R. sup. 1 and R. sup. 2 is a single bond; R. sup. 3c is hydrogen; R. sup. 4c is hydrogen, lower alkyl, lower cycloalkyl, lower alkenyl, alkanoyl of 2-6 carbons, --(CH. sub. 2). sub. m CO. sub. 2 R. sup. 16, --(CH. sub. 2). sub. m Ar. sup. a, --(CH. sub. 2). sub. n 'CONR. sup. 17 R. sup. 18, --(CH. sub. 2). sub. n 'NR. sup. 17 R. sup. 18 or --(CH. sub. 2). sub. n 'OR. sup.

5708001, Jan 13, 1998

Jun 7, 1995

8/454166

Robert Carl Andrews - Durham NC
Cynthia Markert Cribbs - Raleigh NC
Stephen Vernon Frye - Durham NC
Curt Dale Haffner - Cary NC
Patrick Reed Maloney - Durham NC

Glaxo Wellcome Inc. - Research Triangle Park NC

A61K 3158, C07D22118

514284

The present invention relates to certain substituted 17. beta. -substituted carbonyl-6-azaandrost-4-en-3-ones of formula (I), wherein R. sup. 1 and R. sup. 2 i) are independently hydrogen or lower alkyl and the bond between the carbons bearing R. sup. 1 and R. sup. 2 is a single or a double bond, or ii) taken together are a --CH. sub. 2 -- group forming a cyclopropane ring, and the bond between the carbons bearing R. sup. 1 and R. sup. 2 is a single bond; R. sup. 3 is preferably hydrogen, halogen or lower alkyl, R. sup. 4 is preferably hydrogen or lower alkyl, X is preferably CH. sub. 2, Y is preferably hydrogen and Z is preferably CONR. sup. 14 R. sup. 15 and R. sup. 14 and R. sup. 15 are a variety of organic groups, and pharmaceutically acceptable salts thereof, preparation, medical use and pharmaceutical formulations.